I recall Brennan, the previous ceo, in an interview with Alan Kohler, saying that the company’s revenue potential was about $150M.
That was when the horizon was limited to burns treatment.
I suspect that the cognitively challenged still think that’s what it’s all about.
But the fact that the increase in order volume is twice that of sales says that the product is being rapidly adopted for use in other than burns. And that’s where the far largest TAM is.
NB. In the USA, 200 burns surgeons 7,500 plastic and reconstructive surgeons 18,000 general surgeons.
PNV Price at posting:
$1.79 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)